Lorena DIMA, Daniel VASILE, Liliana ROGOZAE, Muhammad ZIA-UL-HAQ, Shazia Anwer BUKHARI, Marius MOGA

Self-perception of quality of life in patients treated with antipsychotics

Background/aim: Despite extensive research, normal functionality remains problematic in patients with schizophrenia. Issues such as quality of life, subjective well-being, or psychosocial performance are currently objectives of interest. There are limited data collected prospectively on patients' perception of quality of life as compared between treatment groups, especially in developing countries. The aim of the present study was to analyze the evolution of patients' reported quality of life in patients with schizophrenia or related disorders treated with antipsychotics, in naturalistic settings. Materials and methods: The study was designed as a 12-month prospective observational study of 131 subjects with schizophrenia or related disorders treated with haloperidol, olanzapine, risperidone, quetiapine, or aripiprazole, recruited from consecutive hospitalized patients in a psychiatry department. Results: The mean scores for patients' reported quality of life and its components and for satisfaction with treatment had a favorable evolution, but increases were of reduced magnitude. The differences among treatment groups were not statistically significant, with few exceptions. A great variability of data was found. Conclusion: Studies with a stratified analysis by factors influencing quality of life perceptions in this category of patients might allow the identification of differences, if any, between antipsychotics in this domain.

Anahtar Kelimeler:

Antipsychotics, quality of life, schizophrenia

Self-perception of quality of life in patients treated with antipsychotics

Keywords:

Antipsychotics, quality of life, schizophrenia,

PDF

___

Cook PE, Goldberg JO, Van Lieshout RJ. Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Can J Psychiatry 2002; 47: 870–874.
Franz M, Lis S, Plüddemann K, Gallhofer B. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997; 170: 422–425.
Rossler W, Salize HJ, Cucchiaro G, Reinhard I, Kernig C. Does the place of treatment influence the quality of life of schizophrenics? Acta Psychiatr Scand 1999; 100: 142–148.
Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, Awad A. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002; 57: 201–208.
Xiang YT, Wang CY, Wang Y, Chiu HF, Zhao JP, Chen Q, Chan SS, Lee EH, Ungvari GS. Socio-demographic and clinical determinants of quality of life in Chinese patients with schizophrenia: a prospective study. Qual Life Res 2010; 19: 317–322.
Zaghdoudi L, Homri W, Belaid S, Ben Bechir M, Labbane R. Quality of life of patient with schizophrenia treated by conventional and atypical neuroleptics. Tunis Med 2009; 87: 593–598.
Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM Jr. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 1999; 8: 417–426.
Chee KY. Outcome study of first-episode schizophrenia in a developing country: quality of life and antipsychotics. Soc Psychiatry Psychiatr Epidemiol 2009; 44: 143–150.
Reine G, Simeoni MC, Auquier P, Loundou A, Aghababian V, Lancon C. Assessing health-related quality of life in patients suffering from schizophrenia: a comparison of instruments. Eur Psychiatry 2005; 20: 510–519.
Ritsner M, Ponizovsky A, Endicott J, Nechamkin Y, Rauchverger B, Silver H, Modai I. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol 2002; 12: 31–38.
Tempier R, Pawliuk N. Influence of new and conventional antipsychotic medication on subject quality of life. J Psychiatry Neurosci 2001; 26: 131–136.
Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs reference to their subjective tolerability, side effect profit and impact to quality of life. Schizophrenia Res 2000; 43: 135–145.
Nuss P, Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride. Curr Med Res Opin 2010; 26: 787–801.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I: Conceptual framework and item selection. Med Care 1992; 30: 473–483.
Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321–326.
Dima L, Vasile D, Voicu V. Comparative discontinuation rates in patients treated with antipsychotics. Therapeutics Pharm Clin Toxic 2012; 16: 181–189.
Leese M, Schene A, Koeter M, Meijer K, Bindman J, Mazzi M, Puschner B, Burti L, Becker T, Moreno M et al. SF-36 scales, and simple sums of scales, were reliable quality-of-life summaries for patients with schizophrenia. J Clin Epidemiol 2008; 61: 588–596.
Möller HJ. Do effectiveness (“real world”) studies on antipsychotics tell us the real truth? Eur Arch Psychiatry Clin Neurosci 2008; 258: 257–270.
Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl 2000; 401: 3–38.
Jung HY, Hwang SS, Yi JS, Kim Y, Kim YS. Clinician-rated functioning and patient-rated quality of life in schizophrenia: implications of their correspondence for psychopathology and side effects. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 225–230.